JAZZ insider notice: 3,731 common shares via ETRADE on NASDAQ

Rhea-AI Filing Summary

Jazz Pharmaceuticals (JAZZ) filed a Form 144 disclosing a proposed Rule 144 sale of 3,731 shares of common stock with an aggregate market value of $417,872. The notice lists the broker as ETRADE FINANCIAL CORPORATION and an approximate sale date of 08/08/2025 on NASDAQ. The securities were acquired on 08/07/2025 by restricted stock vesting from the issuer and were issued as compensation, with payment dated 08/07/2025. The issuer's total shares outstanding are reported as 60,658,809. The filer reports no securities sold in the past three months and attests they do not possess undisclosed material adverse information.

Insights

Securities Analyst

Routine insider sale of newly vested compensation; information is procedural and appears non-material.

The Form 144 shows a proposed sale of 3,731 common shares valued at $417,872, acquired the day prior via restricted stock vesting and marked as compensation. The use of a broker (ETRADE) and the absence of prior sales in the past three months indicate a standard post-vesting disposal under Rule 144. From the data provided, there are no disclosed operational or financial developments tied to the sale itself.

Corporate Governance Expert

Disclosure aligns with Rule 144 requirements; attestation about material information is included.

The filing includes the required attestation that the filer is unaware of any undisclosed material adverse information and documents acquisition details (restricted stock vesting) and planned sale logistics (broker, exchange, approximate date). The record of no sales in the prior three months and clear labeling of the transaction as compensation support routine insider reporting and governance compliance based on the content provided.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
COMMON	ETRADE FINANCIAL CORPORATION ETRADE FINANCIAL CORPORATION 3 EDISON DRIVE ALPHARETTA GA 30005	3731	417872.00	60658809	08/08/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
COMMON	08/07/2025	RESTRICTED STOCK VESTING	ISSUER			3731	08/07/2025	COMPENSATION

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 for Jazz Pharmaceuticals (JAZZ) disclose?

The notice discloses a proposed sale of 3,731 common shares with an aggregate market value of $417,872 through ETRADE FINANCIAL CORPORATION on NASDAQ, with an approximate sale date of 08/08/2025.

How were the shares acquired according to the filing?

The securities were acquired on 08/07/2025 by restricted stock vesting from the issuer and are described as issued as compensation, with payment dated 08/07/2025.

Has the filer sold any JAZZ securities in the past three months?

The filing states Nothing to Report for securities sold during the past three months.

Who is the listed broker handling the proposed sale?

The broker named in the Form 144 is ETRADE FINANCIAL CORPORATION at the address provided in the notice.

Does the filer attest to knowledge of undisclosed material information?

Yes; the filer represents by signing the notice that they do not know any material adverse information regarding the issuer that has not been publicly disclosed.